MaxCyte, Inc.
Financials
Valuation Metrics
MaxCyte, Inc.'s Market Cap is $123M. At end of 2025 it was $165M. Ranked #3073 of 3,121 in US market (top 98%), #1422 of 1,463 on NASDAQ (top 97%), #198 of 205 in Health Care Equipment & Services (top 97%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $123M | US#3,073/3,121 Sec#198/205 |
| Revenue | $31M | US#2,806/3,121 Sec#197/205 |
| Net Income | $-36M | US—/3,121 Sec—/205 |
| Total Assets | $185M | US#3,008/3,121 Sec#188/205 |
| Net Assets | $159M | US#2,736/3,121 Sec#166/205 |
| Employees | 91 | US#2,647/3,121 Sec#182/205 |
| Value | ||
| P/B | 0.77x | US#205/3,121 Sec#12/205 |
| P/S | 3.96x | US#2,076/3,121 Sec#141/205 |
| FCF Yield | -19.37% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -22.45% | US#2,509/3,121 Sec#151/205 |
| ROA | -19.30% | US#2,789/3,121 Sec#175/205 |
| Op. Margin | -111.63% | US#2,745/3,121 Sec#195/205 |
| Revenue Growth | -13.15% | US#2,639/3,121 Sec#194/205 |
| Financial Health | ||
| Debt Ratio | 16.33% | US#190/3,121 Sec#19/205 |
| Total Debt | $17M | US#2,776/3,121 Sec#177/205 |
| FCF | $-24M | US#2,443/3,121 Sec#162/205 |
| Cash | $15M | US#2,916/3,121 Sec#193/205 |
| Current Ratio | 12.26x | US#207/3,121 Sec#5/205 |
| Performance | ||
| 1Y Return | -26.54% | US#2,405/3,121 Sec#161/205 |
| 1M Return | -14.39% | US#1,878/3,121 Sec#148/205 |
| From 52W High | -36.36% | US#2,347/3,121 Sec#155/205 |
| 1Y MDD | -62.90% | US#2,839/3,121 Sec#178/205 |
| Trading | ||
| Volume | 433,040 shares | US#2,530/3,121 Sec#177/205 |
| Trading Value | $515317.00 | US#3,093/3,121 Sec#203/205 |
| Per Share | ||
| EPS | $-0.35 | US—/3,121 Sec—/205 |
| BPS | $1.54 | US#2,632/3,121 Sec#173/205 |
Company Info
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.